Skip to main content
Erschienen in: Annals of Hematology 7/2006

01.07.2006 | Review Article

Von Willebrand factor and thrombosis

verfasst von: Massimo Franchini, Giuseppe Lippi

Erschienen in: Annals of Hematology | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

There is increasing evidence that von Willebrand factor (VWF), an adhesive multimeric protein that has an important function in primary hemostasis and as a carrier of factor VIII, has a pivotal role in thrombogenesis. In fact, while the presence in plasma of unusually large VWF multimers due to a congenital or acquired deficiency of a VWF-cleaving metalloprotease has been implicated in the pathogenesis of thrombotic thrombocytopenic purpura (TTP), high plasma levels of VWF have been associated with a slightly increased risk of arterial thrombosis. With regard to the association between VWF and venous thrombosis, clear conclusions cannot yet be drawn from the conflicting published data. Patients with von Willebrand disease, an inherited hemorrhagic disorder, may also paradoxically experience thrombotic events as a result of interactions among multiple prothrombotic risk factors. After a description of the structure and physiology of VWF, all these aspects are discussed in the present review.
Literatur
1.
Zurück zum Zitat Weiss HJ, Sussman II, Hoyer LW (1977) Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest 60:390–404PubMedCrossRef Weiss HJ, Sussman II, Hoyer LW (1977) Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest 60:390–404PubMedCrossRef
2.
Zurück zum Zitat Sakariassen KS, Bolhuis PA, Sixma JJ (1979) Human blood platelet adhesion to artery subendothelium is mediated by factor VIII–Von Willebrand factor bound to the subendothelium. Nature 279:636–638PubMedCrossRef Sakariassen KS, Bolhuis PA, Sixma JJ (1979) Human blood platelet adhesion to artery subendothelium is mediated by factor VIII–Von Willebrand factor bound to the subendothelium. Nature 279:636–638PubMedCrossRef
3.
Zurück zum Zitat Martinelli I (2005) Von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 42:49–55PubMedCrossRef Martinelli I (2005) Von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 42:49–55PubMedCrossRef
4.
Zurück zum Zitat Franchini M (2004) Thrombotic complications in patients with hereditary bleeding disorders. Thromb Haemost 92:298–304PubMed Franchini M (2004) Thrombotic complications in patients with hereditary bleeding disorders. Thromb Haemost 92:298–304PubMed
5.
Zurück zum Zitat Soejima K, Nakagaki T (2005) Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies. Semin Hematol 42:56–62PubMedCrossRef Soejima K, Nakagaki T (2005) Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies. Semin Hematol 42:56–62PubMedCrossRef
6.
Zurück zum Zitat Castaman G, Federici AB, Rodeghiero F, Mannucci PM (2003) Von Willebrand’s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 88:94–108PubMed Castaman G, Federici AB, Rodeghiero F, Mannucci PM (2003) Von Willebrand’s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 88:94–108PubMed
7.
Zurück zum Zitat Mancuso DJ, Tuley EA, Westfield LA, Lester-Mancuso TL, Le Beau MM, Sorace JM, Sadler JE (1991) Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 30:253–269PubMedCrossRef Mancuso DJ, Tuley EA, Westfield LA, Lester-Mancuso TL, Le Beau MM, Sorace JM, Sadler JE (1991) Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 30:253–269PubMedCrossRef
8.
Zurück zum Zitat Sadler JE, Mancuso DJ, Randi AM, Tuley EA, Westfield LA (1991) Molecular biology of von Willebrand factor. Ann NY Acad Sci 614:114–124PubMedCrossRef Sadler JE, Mancuso DJ, Randi AM, Tuley EA, Westfield LA (1991) Molecular biology of von Willebrand factor. Ann NY Acad Sci 614:114–124PubMedCrossRef
9.
Zurück zum Zitat Mendolicchio GL, Ruggeri ZM (2005) New perspectives on von Willebrand factor functions in hemostasis and thrombosis. Semin Hematol 42:5–14PubMedCrossRef Mendolicchio GL, Ruggeri ZM (2005) New perspectives on von Willebrand factor functions in hemostasis and thrombosis. Semin Hematol 42:5–14PubMedCrossRef
10.
12.
Zurück zum Zitat Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100:4033–4039PubMedCrossRef Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100:4033–4039PubMedCrossRef
13.
Zurück zum Zitat Schmugge M, Rand ML, Freedman J (2003) Platelets and von Willebrand factor. Transfus Apher Sci 28:269–277PubMedCrossRef Schmugge M, Rand ML, Freedman J (2003) Platelets and von Willebrand factor. Transfus Apher Sci 28:269–277PubMedCrossRef
14.
Zurück zum Zitat Ruggeri ZM (2001) Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 14:257–279PubMedCrossRef Ruggeri ZM (2001) Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 14:257–279PubMedCrossRef
15.
Zurück zum Zitat Ruggeri ZM (2000) Old concepts and new developments in the study of platelet aggregation. J Clin Invest 105:699–701PubMedCrossRef Ruggeri ZM (2000) Old concepts and new developments in the study of platelet aggregation. J Clin Invest 105:699–701PubMedCrossRef
16.
Zurück zum Zitat Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ (1998) Factor VIII and von Willebrand factor. Thromb Haemost 79:456–465PubMed Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ (1998) Factor VIII and von Willebrand factor. Thromb Haemost 79:456–465PubMed
17.
Zurück zum Zitat Cattaneo M (2001) Role of von Willebrand factor in atherothrombosis. Haematologica 86:3–5 Cattaneo M (2001) Role of von Willebrand factor in atherothrombosis. Haematologica 86:3–5
18.
Zurück zum Zitat Yamashita A, Asada Y, Sugimura H, Yamamoto H, Marutsuka K, Hatakeyama K, Tamura S, Ikeda Y, Sumiyoshi A (2003) Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity. Arterioscler Thromb Vasc Biol 23:1105–1110PubMedCrossRef Yamashita A, Asada Y, Sugimura H, Yamamoto H, Marutsuka K, Hatakeyama K, Tamura S, Ikeda Y, Sumiyoshi A (2003) Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity. Arterioscler Thromb Vasc Biol 23:1105–1110PubMedCrossRef
19.
Zurück zum Zitat Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69:1691–1695PubMed Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69:1691–1695PubMed
20.
Zurück zum Zitat Jeremic M, Weisert O, Gedde-Dahl TW (1976) Factor VIII (AHG) levels in 1016 regular blood donors. The effects of age, sex, and ABO blood groups. Scand J Clin Lab Invest 36:461–466PubMedCrossRef Jeremic M, Weisert O, Gedde-Dahl TW (1976) Factor VIII (AHG) levels in 1016 regular blood donors. The effects of age, sex, and ABO blood groups. Scand J Clin Lab Invest 36:461–466PubMedCrossRef
21.
Zurück zum Zitat Mannucci PM (1998) Von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 18:1359–1362PubMed Mannucci PM (1998) Von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 18:1359–1362PubMed
22.
Zurück zum Zitat Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ (1994) Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 88:601–607PubMedCrossRef Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ (1994) Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 88:601–607PubMedCrossRef
23.
Zurück zum Zitat Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332:635–641PubMedCrossRef Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332:635–641PubMedCrossRef
24.
Zurück zum Zitat Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE (1997) Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96:1102–1108PubMed Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE (1997) Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96:1102–1108PubMed
25.
Zurück zum Zitat Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK (1999) Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100:736–742PubMed Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK (1999) Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100:736–742PubMed
26.
Zurück zum Zitat Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD (1997) Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 17:3321–3325PubMed Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD (1997) Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 17:3321–3325PubMed
27.
Zurück zum Zitat Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP (1995) Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart study. Br J Haematol 105:110–116CrossRef Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP (1995) Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart study. Br J Haematol 105:110–116CrossRef
28.
Zurück zum Zitat Jansson JH, Nilsson TK, Johnson O (1998) Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 80:334–337PubMed Jansson JH, Nilsson TK, Johnson O (1998) Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 80:334–337PubMed
29.
Zurück zum Zitat Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD (2002) Von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23:1764–1770PubMedCrossRef Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD (2002) Von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23:1764–1770PubMedCrossRef
30.
Zurück zum Zitat Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD (1999) Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19:3071–3078PubMed Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD (1999) Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19:3071–3078PubMed
31.
Zurück zum Zitat Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I; on behalf of the PRIME study (2004) Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109:1343–1348PubMedCrossRef Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I; on behalf of the PRIME study (2004) Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109:1343–1348PubMedCrossRef
32.
Zurück zum Zitat van der Meer IM, Brouwers GJ, Bulk S, Leebeek FW, van der Kuip DA, Hofman A, Witteman JC, Gomez Garcia EB (2004) Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol 124:343–347PubMedCrossRef van der Meer IM, Brouwers GJ, Bulk S, Leebeek FW, van der Kuip DA, Hofman A, Witteman JC, Gomez Garcia EB (2004) Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol 124:343–347PubMedCrossRef
33.
Zurück zum Zitat Sramek A, Bucciarelli P, Federici AB et al (2004) Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation 109:740–744PubMedCrossRef Sramek A, Bucciarelli P, Federici AB et al (2004) Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation 109:740–744PubMedCrossRef
34.
Zurück zum Zitat Stead NW, Bauer KA, Kinney TR, Lewis JG, Campbell EE, Shifman MA, Rosenberg RD, Pizzo SV (1983) Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand’s factor. Am J Med 74:33–39PubMedCrossRef Stead NW, Bauer KA, Kinney TR, Lewis JG, Campbell EE, Shifman MA, Rosenberg RD, Pizzo SV (1983) Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand’s factor. Am J Med 74:33–39PubMedCrossRef
35.
Zurück zum Zitat Nilsson T, Mellbring G, Hedner U (1986) Relationship between factor XII, von Willebrand factor and postoperative deep vein thrombosis. Acta Chir Scand 152:347–349PubMed Nilsson T, Mellbring G, Hedner U (1986) Relationship between factor XII, von Willebrand factor and postoperative deep vein thrombosis. Acta Chir Scand 152:347–349PubMed
36.
Zurück zum Zitat Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152–155PubMedCrossRef Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152–155PubMedCrossRef
37.
Zurück zum Zitat Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR (2002) Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 113:636–642PubMedCrossRef Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR (2002) Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 113:636–642PubMedCrossRef
38.
Zurück zum Zitat Bucek RA, Reiter M, Quehenberger P, Weltermann A, Kyrle PA, Minar E (2003) Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters? Br J Haematol 120:123–128 Bucek RA, Reiter M, Quehenberger P, Weltermann A, Kyrle PA, Minar E (2003) Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters? Br J Haematol 120:123–128
39.
Zurück zum Zitat Kamphuisen PW, Eikenboom JC, Rosendaal FR, Koster T, Blann AD, Vos HL, Bertina RM (2001) High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 115:156–158PubMedCrossRef Kamphuisen PW, Eikenboom JC, Rosendaal FR, Koster T, Blann AD, Vos HL, Bertina RM (2001) High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 115:156–158PubMedCrossRef
40.
41.
Zurück zum Zitat Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K (1985) Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 38:469–479PubMedCrossRef Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K (1985) Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 38:469–479PubMedCrossRef
42.
Zurück zum Zitat Ruggenenti P, Noris M, Remuzzi G (2001) Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60:831–846PubMedCrossRef Ruggenenti P, Noris M, Remuzzi G (2001) Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60:831–846PubMedCrossRef
43.
Zurück zum Zitat Tsai HM (2003) Deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 23:388–396PubMedCrossRef Tsai HM (2003) Deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 23:388–396PubMedCrossRef
44.
Zurück zum Zitat Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432–1435PubMed Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432–1435PubMed
45.
Zurück zum Zitat Furlan M, Robles R, Lämmle B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223–4234PubMed Furlan M, Robles R, Lämmle B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223–4234PubMed
46.
Zurück zum Zitat Tsai HM (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235–4244PubMed Tsai HM (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235–4244PubMed
47.
Zurück zum Zitat Furlan M, Robles R, Solenthaler M, Lämmle B (1998) Acquired deficiency of von Willebrand factor cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 91:2839–2846PubMed Furlan M, Robles R, Solenthaler M, Lämmle B (1998) Acquired deficiency of von Willebrand factor cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 91:2839–2846PubMed
48.
Zurück zum Zitat Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594PubMedCrossRef Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594PubMedCrossRef
49.
Zurück zum Zitat Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 339:1578–1584PubMedCrossRef Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 339:1578–1584PubMedCrossRef
50.
Zurück zum Zitat Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathy: a study of 111 cases. Blood 98:1765–1772PubMedCrossRef Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathy: a study of 111 cases. Blood 98:1765–1772PubMedCrossRef
51.
Zurück zum Zitat Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98:1662–1666PubMedCrossRef Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98:1662–1666PubMedCrossRef
52.
Zurück zum Zitat Gerritsen HE, Robles R, Lämmle B, Furlan M (2001) Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98:1654–1661PubMedCrossRef Gerritsen HE, Robles R, Lämmle B, Furlan M (2001) Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98:1654–1661PubMedCrossRef
53.
Zurück zum Zitat Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K (2001) Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059–41063PubMedCrossRef Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K (2001) Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059–41063PubMedCrossRef
54.
Zurück zum Zitat Plaimauer B, Zimemrmann K, Völkel D, Antoine G, Kerschbaumer R, Jenab P, Furlan M, Gerritsen H, Lammle B, Schwarz HP, Scheiflinger F (2002) Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 100:3626–3632PubMedCrossRef Plaimauer B, Zimemrmann K, Völkel D, Antoine G, Kerschbaumer R, Jenab P, Furlan M, Gerritsen H, Lammle B, Schwarz HP, Scheiflinger F (2002) Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 100:3626–3632PubMedCrossRef
55.
Zurück zum Zitat Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494PubMedCrossRef Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494PubMedCrossRef
56.
Zurück zum Zitat Bowen D, Dasani H, Yung B, Bloom A (1992) Deep venous thrombosis and pulmonary embolism in a patient with type III von Willebrand’s disease, protein C and antithrombin III deficiency. Br J Haematol 81:446–447PubMedCrossRef Bowen D, Dasani H, Yung B, Bloom A (1992) Deep venous thrombosis and pulmonary embolism in a patient with type III von Willebrand’s disease, protein C and antithrombin III deficiency. Br J Haematol 81:446–447PubMedCrossRef
57.
Zurück zum Zitat Franchini M, Krampera M, Veneri D (2003) Deep vein thrombosis after orthopedic surgery in a patient with type 1 von Willebrand disease and mutations in the MTHFR and beta-fibrinogen genes. Thromb Haemost 90:963–964PubMed Franchini M, Krampera M, Veneri D (2003) Deep vein thrombosis after orthopedic surgery in a patient with type 1 von Willebrand disease and mutations in the MTHFR and beta-fibrinogen genes. Thromb Haemost 90:963–964PubMed
58.
Zurück zum Zitat Franchini M, Veneri D (2004) Are only hemophiliacs protected against ischemic heart disease? Thromb Haemost 92:1455–1456PubMed Franchini M, Veneri D (2004) Are only hemophiliacs protected against ischemic heart disease? Thromb Haemost 92:1455–1456PubMed
59.
Zurück zum Zitat Fragasso G, Camba L, Pizzetti G, Pagnotta P, Chierchia SL (1998) Successful thrombolysis for acute myocardial infarction in type 1 von Willebrand’s disease (vWD). Am J Hematol 57:180PubMedCrossRef Fragasso G, Camba L, Pizzetti G, Pagnotta P, Chierchia SL (1998) Successful thrombolysis for acute myocardial infarction in type 1 von Willebrand’s disease (vWD). Am J Hematol 57:180PubMedCrossRef
60.
Zurück zum Zitat Mannucci PM (2002) Venous thromboembolism in von Willebrand disease. Thromb Haemost 88:378–379PubMed Mannucci PM (2002) Venous thromboembolism in von Willebrand disease. Thromb Haemost 88:378–379PubMed
61.
62.
Zurück zum Zitat Ruggeri ZM (2004) Type IIB von Willebrand disease: a paradox explains how von Willebrand factor works. J Thromb Haemost 2:2–6PubMedCrossRef Ruggeri ZM (2004) Type IIB von Willebrand disease: a paradox explains how von Willebrand factor works. J Thromb Haemost 2:2–6PubMedCrossRef
63.
Zurück zum Zitat Savage B, Saldivar E, Ruggeri ZM (1996) Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84:289–297PubMedCrossRef Savage B, Saldivar E, Ruggeri ZM (1996) Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84:289–297PubMedCrossRef
64.
Zurück zum Zitat Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE (2000) Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem 275:7539–7546PubMedCrossRef Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE (2000) Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem 275:7539–7546PubMedCrossRef
65.
Zurück zum Zitat Makris M, Colvin B, Gupta V, Shields ML, Smith MP (2002) Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost 88:387–388PubMed Makris M, Colvin B, Gupta V, Shields ML, Smith MP (2002) Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost 88:387–388PubMed
66.
Zurück zum Zitat Mannucci PM, Chediak J, Hanna W, Byrnes J, Marlies L, Ewenstein BM, and the Alphanate Study Group (2002) Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99:450–456PubMedCrossRef Mannucci PM, Chediak J, Hanna W, Byrnes J, Marlies L, Ewenstein BM, and the Alphanate Study Group (2002) Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99:450–456PubMedCrossRef
67.
Zurück zum Zitat Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G (2003) Efficacy and safety of factor VIII/ von Willebrand factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand’s disease. Haematologica 88:1279–1283PubMed Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G (2003) Efficacy and safety of factor VIII/ von Willebrand factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand’s disease. Haematologica 88:1279–1283PubMed
68.
Zurück zum Zitat Rosendaal FR (2000) High levels of factor VIII and venous thrombosis. Throm Haemost 83:1–2 Rosendaal FR (2000) High levels of factor VIII and venous thrombosis. Throm Haemost 83:1–2
69.
Zurück zum Zitat Mannucci PM (2004) Treatment of von Willebrand’s disease. N Engl J Med 35:683–694CrossRef Mannucci PM (2004) Treatment of von Willebrand’s disease. N Engl J Med 35:683–694CrossRef
70.
Zurück zum Zitat Basso IN, Keeling D (2004) Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagul Fibrinolysis 15:503–504PubMedCrossRef Basso IN, Keeling D (2004) Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagul Fibrinolysis 15:503–504PubMedCrossRef
71.
Zurück zum Zitat Goodnough LT, Saito H, Ratnoff OD (1983) Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 62:248–255 Goodnough LT, Saito H, Ratnoff OD (1983) Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 62:248–255
72.
Zurück zum Zitat Dulhoste MN, Bonnet J, Vergnes C, Choussat A, Bricaud H (1989) Von Willebrand's disease and coronary atherosclerosis. Apropos of 3 cases. Arch Mal Coeur Vaiss 82:1875–1878PubMed Dulhoste MN, Bonnet J, Vergnes C, Choussat A, Bricaud H (1989) Von Willebrand's disease and coronary atherosclerosis. Apropos of 3 cases. Arch Mal Coeur Vaiss 82:1875–1878PubMed
73.
Zurück zum Zitat Girolami A, Cappellato MG, Vicarioto MA, Casonato S, Marafioti F (1986) Associated von Willebrand disease as a possible cause of lack of thrombosis in an AT III abnormality (AT III Trento). Blut 52:29–33PubMedCrossRef Girolami A, Cappellato MG, Vicarioto MA, Casonato S, Marafioti F (1986) Associated von Willebrand disease as a possible cause of lack of thrombosis in an AT III abnormality (AT III Trento). Blut 52:29–33PubMedCrossRef
74.
Zurück zum Zitat van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van der Berg HM (2004) Do prothrombotic factors influence clinical phenotype of severe hemophilia? A review of the literature. Thromb Haemost 92:305–310PubMed van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van der Berg HM (2004) Do prothrombotic factors influence clinical phenotype of severe hemophilia? A review of the literature. Thromb Haemost 92:305–310PubMed
75.
Zurück zum Zitat Weiss HJ (2004) The bleeding tendency in patients with low von Willebrand factor and type 1 phenotype is greater in the presence of impaired collagen-induced platelet aggregation. J Thromb Haemost 2:198–199PubMedCrossRef Weiss HJ (2004) The bleeding tendency in patients with low von Willebrand factor and type 1 phenotype is greater in the presence of impaired collagen-induced platelet aggregation. J Thromb Haemost 2:198–199PubMedCrossRef
76.
Zurück zum Zitat Kunicki TJ, Federici AB, Salomon DR, Koziol JA, Head SR, Mondala TS, Chismar JD, Baronciani L, Canciani MT, Peake IR (2004) An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood 104:2359–2367PubMedCrossRef Kunicki TJ, Federici AB, Salomon DR, Koziol JA, Head SR, Mondala TS, Chismar JD, Baronciani L, Canciani MT, Peake IR (2004) An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood 104:2359–2367PubMedCrossRef
77.
Zurück zum Zitat Bond L, Bevan D (1988) Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 318:121PubMed Bond L, Bevan D (1988) Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 318:121PubMed
78.
Zurück zum Zitat Byrnes JJ, Larcada A, Moake JL (1988) Thrombosis following desmopressin for uremic bleeding. Am J Hematol 28:63–65PubMedCrossRef Byrnes JJ, Larcada A, Moake JL (1988) Thrombosis following desmopressin for uremic bleeding. Am J Hematol 28:63–65PubMedCrossRef
80.
Zurück zum Zitat van Dantzig JM (1989) Desmopressin and myocardial infarction. Lancet 1:664–665 van Dantzig JM (1989) Desmopressin and myocardial infarction. Lancet 1:664–665
Metadaten
Titel
Von Willebrand factor and thrombosis
verfasst von
Massimo Franchini
Giuseppe Lippi
Publikationsdatum
01.07.2006
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 7/2006
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-006-0085-5

Weitere Artikel der Ausgabe 7/2006

Annals of Hematology 7/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.